ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

First Two Patients Respond to Gene Therapy in Melanoma Study

by Paula Moyer • November 1, 2006

  • Tweet
  • Email
Print-Friendly Version
Bert W. O'Malley, Jr., MD

You Might Also Like

  • Gene Therapy: A Promising Role in Otolaryngology
  • Targeted Therapy a Potential Treatment for Head and Neck Cancer
  • Patients Respond to Oral BRAF Inhibitor
  • Laser Treatment Resolves Glottic Cancer in a Pilot Study
Explore This Issue
November 2006
Bert W. O’Malley, Jr., MD

Gene therapy as a treatment for cancer has advanced from the theoretical to the possible: in a pilot study published in August in the journal Science, investigators reported that two of 17 patients with advanced melanoma responded to a treatment known as genetically engineered therapy.

Genetically engineered gene therapy uses autologous T-cells that are extracted and cultured and treated with cytokines. Therefore, when they are reimplanted, they can activate the immune system.

In a study led by Steven A. Rosenberg, MD, PhD, chief of surgery at the National Cancer Institute in Bethesda, Md., investigators harvested one patient’s T-cells and genetically isolated the T-cell receptor so that it would be specific to melanoma. They then removed T-cells from 17 melanoma patients and genetically spliced in the one patient’s tumor-specific receptors. Finally, they cultured those cells and transfused them into the patients. Among these patients, the investigators documented “dramatic and durable regression” of the tumors in two patients.

This study is one of several steps in a long process to develop immunotherapy approaches for the treatment of metastatic melanoma, said Dr. Rosenberg in a phone interview. “We have studied immunotherapy for the treatment of metastatic melanoma, and we have reported on cell transfer therapies that represent the most effective treatment for metastatic melanoma.”

Genetically engineered gene therapy may offer promise for refractory cases, he said. “If otolaryngologists have patients with metastatic melanoma, and it’s refractory to standard treatments, we may have something for them,” he said. “The ongoing clinical trials are continuing to show the promise reflected in the recently published trial. If a physician has patients with refractory metastatic melanoma, he or she should consider referring such patients for one of these newer cell transfer therapies.”

An Important First Step

Two gene therapy experts who were not involved in the study stressed that the findings are exciting despite the fact that only two patients had responded at the time of publication.

“The exciting thing about the current research is that the investigators took cells from the blood and made them cancer-specific,” said Andrew G. Sikora, MD, PhD, in a phone interview. Dr. Sikora, who was not involved in the current research, is a clinical fellow in Head and Neck Surgery at the M. D. Anderson Cancer Center in Houston. “It’s one of the first studies utilizing gene therapy in which patients have had a positive response to treatment.” Dr. Sikora, who is currently doing cancer immunology research with the department of Melanoma Medical Oncology, also pointed out that the investigators in the current study treated patients with the most advanced disease states. “If the approach is validated in patients with serious, advanced melanoma, it may be that patients who have less advanced disease have a better chance of responding to it,” he said.

Pages: 1 2 3 | Single Page

Filed Under: Departments, Head and Neck, Medical Education, Practice Focus Tagged With: cancer, carcinoma, genes, immunotherapy, melanoma, outcomes, research, treatmentIssue: November 2006

You Might Also Like:

  • Gene Therapy: A Promising Role in Otolaryngology
  • Targeted Therapy a Potential Treatment for Head and Neck Cancer
  • Patients Respond to Oral BRAF Inhibitor
  • Laser Treatment Resolves Glottic Cancer in a Pilot Study

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Weaning Patients Off of PPIs
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Did You Receive COVID-19 Relief? Here Are Reporting Considerations for 2021
    • Otolaryngology Experts Share Best Practices in Five Areas
    • How Climate Change May Be Affecting Sleep Patterns for Adults and Children
    • Laryngologists Discuss Tough Tracheostomy Choices During COVID-19 Era
    • Head and Neck Cancer: Experts Discuss How to Improve Surgery Quality and Value

Polls

Did you receive funding from the CARES Act or Paycheck Protection Program?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.